Total Payments
$643,481
2024 Payments
$93,421
Companies
27
Transactions
926
Medicare Patients
2,618
Medicare Billing
$714,059
Payment Breakdown by Category
Other$391,041 (60.8%)
Consulting$120,401 (18.7%)
Travel$63,875 (9.9%)
Research$53,087 (8.2%)
Food & Beverage$14,995 (2.3%)
Education$81.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $382,293 | 192 | 59.4% |
| Consulting Fee | $120,401 | 63 | 18.7% |
| Travel and Lodging | $63,875 | 417 | 9.9% |
| Unspecified | $53,087 | 4 | 8.2% |
| Food and Beverage | $14,995 | 244 | 2.3% |
| Honoraria | $8,748 | 3 | 1.4% |
| Education | $81.67 | 3 | 0.0% |
Payments by Type
General
$590,393
922 transactions
Research
$53,087
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $349,286 | 695 | $0 (2020) |
| Remel, Inc. | $94,574 | 50 | $0 (2024) |
| ABBVIE INC. | $77,112 | 79 | $0 (2024) |
| Eli Lilly and Company | $51,582 | 3 | $0 (2021) |
| Melinta Therapeutics, LLC | $24,725 | 23 | $0 (2024) |
| AIMMUNE THERAPEUTICS, INC. | $12,240 | 8 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $10,866 | 7 | $0 (2023) |
| Paratek Pharmaceuticals, Inc. | $5,386 | 8 | $0 (2019) |
| TETRAPHASE PHARMACEUTICALS, INC. | $4,944 | 4 | $0 (2019) |
| Insmed, Inc. | $3,265 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $93,421 | 89 | ABBVIE INC. ($50,729) |
| 2023 | $49,276 | 47 | ABBVIE INC. ($20,265) |
| 2022 | $20,536 | 21 | Remel, Inc. ($14,400) |
| 2021 | $11,380 | 6 | Remel, Inc. ($4,800) |
| 2020 | $76,190 | 58 | Eli Lilly and Company ($49,142) |
| 2019 | $165,270 | 358 | Allergan Inc. ($136,014) |
| 2018 | $161,080 | 263 | Allergan Inc. ($135,700) |
| 2017 | $66,327 | 84 | Allergan Inc. ($55,401) |
All Payment Transactions
926 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $287.50 | General |
| 12/20/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/12/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Consulting Fee | Cash or cash equivalent | $1,840.00 | General |
| Category: ANTIFUNGALS | ||||||
| 12/12/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Consulting Fee | Cash or cash equivalent | $1,275.00 | General |
| Category: ANTIFUNGALS | ||||||
| 12/03/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/03/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO | Travel and Lodging | In-kind items and services | $18.76 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/03/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Travel and Lodging | In-kind items and services | $8.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/27/2024 | Remel, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 11/25/2024 | ABBVIE INC. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/18/2024 | ABBVIE INC. | DALVANCE (Drug) | Consulting Fee | Cash or cash equivalent | $575.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/15/2024 | ABBVIE INC. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,725.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/09/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: Infections and Infectious Diseases | ||||||
| 11/01/2024 | ABBVIE INC. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $857.47 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/01/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/31/2024 | Remel, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 10/14/2024 | ABBVIE INC. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,875.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/04/2024 | ABBVIE INC. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,025.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/01/2024 | Remel, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 10/01/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/01/2024 | ABBVIE INC. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $58.96 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/18/2024 | ABBVIE INC. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $112.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/17/2024 | ABBVIE INC. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $535.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/17/2024 | ABBVIE INC. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $286.25 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/17/2024 | ABBVIE INC. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $256.78 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/17/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ANTI-INFECTIVE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH COVID 19 INFECTION | Eli Lilly and Company | $51,582 | 3 |
| Long Term Follow Up Study of Patients with COVID 19 Associated Pneumonia Who Participated in a Desig | F. Hoffmann-La Roche AG | $1,505 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 693 | 2,070 | $508,805 | $222,677 |
| 2022 | 4 | 811 | 2,193 | $549,060 | $224,302 |
| 2021 | 4 | 576 | 1,501 | $369,795 | $154,473 |
| 2020 | 4 | 538 | 1,109 | $243,735 | $112,607 |
Total Patients
2,618
Total Services
6,873
Medicare Billing
$714,059
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 343 | 1,590 | $333,900 | $157,643 | 47.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 252 | 275 | $107,250 | $38,760 | 36.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 46 | 121 | $55,055 | $20,838 | 37.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 52 | 84 | $12,600 | $5,436 | 43.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 367 | 1,543 | $324,030 | $132,780 | 41.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 314 | 356 | $138,840 | $57,188 | 41.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 48 | 138 | $62,790 | $24,974 | 39.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 82 | 156 | $23,400 | $9,359 | 40.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 263 | 1,070 | $224,700 | $93,860 | 41.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 202 | 217 | $84,630 | $35,848 | 42.4% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 32 | 93 | $42,315 | $17,370 | 41.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 79 | 121 | $18,150 | $7,396 | 40.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 208 | 555 | $107,250 | $50,053 | 46.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 149 | 156 | $56,088 | $27,312 | 48.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 147 | 317 | $44,400 | $19,831 | 44.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 34 | 81 | $35,997 | $15,412 | 42.8% |
About Dr. James Mckinnell, M.D
Dr. James Mckinnell, M.D is a Infectious Disease healthcare provider based in Torrance, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1942403035.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Mckinnell, M.D has received a total of $643,481 in payments from pharmaceutical and medical device companies, with $93,421 received in 2024. These payments were reported across 926 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($382,293).
As a Medicare-enrolled provider, Mckinnell has provided services to 2,618 Medicare beneficiaries, totaling 6,873 services with total Medicare billing of $714,059. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Hospice and Palliative Medicine
- Location Torrance, CA
- Active Since 06/07/2007
- Last Updated 10/21/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1942403035
Products in Payments
- AVYCAZ (Drug) $289,293
- DALVANCE (Drug) $79,412
- TEFLARO (Drug) $53,238
- ZENPEP (Drug) $12,240
- REBYOTA (Biological) $6,726
- Kimyrsa (Drug) $5,991
- NUZYRA (Drug) $5,386
- Xerava (Drug) $4,944
- Arikayce (Drug) $3,265
- Rezzayo (Drug) $3,115
- Vabomere (Drug) $3,018
- SOLIRIS (Biological) $1,840
- Actemra (Biological) $1,505
- Fetroja (Drug) $1,201
- ACCELERATE PHENO (Device) $863.24
- CRESEMBA (Drug) $107.62
- Xofluza (Drug) $76.00
- DIFICID (Drug) $71.62
- ZERBAXA (Drug) $32.21
- XARELTO (Drug) $29.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Torrance
Mr. Behzad Noorian, Md, MD
Infectious Disease — Payments: $121,149
Infectious Disease $121,149
Eric Daar, M.d, M.D
Infectious Disease — Payments: $73,932
Infectious Disease $73,932
Brad Spellberg, M.d, M.D
Infectious Disease — Payments: $56,183
Infectious Disease $56,183
Loren Miller, M.d, M.D
Infectious Disease — Payments: $22,180
Infectious Disease $22,180
Mallory Witt, M.d, M.D
Infectious Disease — Payments: $7,542
Infectious Disease $7,542
Scott Filler, M.d, M.D
Infectious Disease — Payments: $7,250
Infectious Disease $7,250